INTRODUCTION Cutaneous adverse events (AE) are the most prevalent toxicity under checkpoint-inhibitors in clinical trials. In “real-life” conditions of use, skin toxicities under anti-PD-1 have not been described to date in a large cohort. The objective of this study was to determine the clinical features of skin toxicities in patients with…[Read more]